Disclosures for "Management of Intractable Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage with the eShunt® System Endovascular CSF Shunt "
-
Prof. Lylyk has nothing to disclose.
-
Dr. Lylyk has nothing to disclose.
-
Dr. Bleise has nothing to disclose.
-
Dr. Scrivano has nothing to disclose.
-
Mr. Lylyk has nothing to disclose.
-
Mr. Beneduce has received personal compensation for serving as an employee of CereVasc. Mr. Beneduce has stock in CereVasc.
-
Dr. Heilman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Cerevasc Inc. Dr. Heilman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neurosurgery. Dr. Heilman has stock in Cerevasc, Inc. Dr. Heilman has received intellectual property interests from a discovery or technology relating to health care.
-
Prof. Malek has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for CereVasc Inc.. Prof. Malek has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerus Endovascular/Stryker. Prof. Malek has stock in CereVasc Inc.. Prof. Malek has received intellectual property interests from a discovery or technology relating to health care.